GSK reports nine-month 2026 profit after taxation of USD 5.49 billion; turnover totals USD 33.4 billion
GSK•GSK reported profit attributable to shareholders of GBP 3.72 billion and turnover of GBP 24.93 billion for the nine months ended September 30, 2026.
1. Nine-month results
GSK reported profit attributable to shareholders of GBP 3.72 billion for the nine months ended September 30, 2026. Turnover totaled GBP 24.93 billion, including GBP 10.89 billion from Specialty Medicines, GBP 7.02 billion from Vaccines and GBP 7.02 billion from General Medicines.
